Back to top
more

PROCEPT BioRobotics (PRCT)

(Real Time Quote from BATS)

$89.35 USD

89.35
437,641

+3.44 (4.00%)

Updated Nov 15, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for PRCT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for PROCEPT BioRobotics Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 257 223 304 100 -99,999
Receivables 48 15 4 2 NA
Notes Receivable 0 0 0 0 NA
Inventories 40 29 13 7 NA
Other Current Assets 5 6 4 2 NA
Total Current Assets 351 273 326 110 NA
Net Property & Equipment 29 9 5 8 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 1 1 2 2 NA
Deposits & Other Assets 4 3 1 1 NA
Total Assets 405 309 337 126 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 5 NA
Accounts Payable 14 9 2 1 NA
Current Portion Long-Term Debt 2 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 17 13 6 5 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 12 10 6 2 NA
Total Current Liabilities 46 35 16 15 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 51 53 52 46 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 1 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 124 112 70 65 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 244 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 735 546 529 19 NA
Retained Earnings -455 -349 -262 -202 NA
Other Equity 0 0 0 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 281 197 267 61 NA
Total Liabilities & Shareholder's Equity 405 309 337 126 NA
Total Common Equity 281 197 267 -183 0
Shares Outstanding 50.50 44.70 43.50 NA NA
Book Value Per Share 5.56 4.41 6.14 0.00 0.00

Fiscal Year End for PROCEPT BioRobotics Corporation falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents 197 214 226 257 288
Receivables 69 59 56 48 35
Notes Receivable 0 0 0 0 0
Inventories 51 44 42 40 42
Other Current Assets 6 5 6 5 4
Total Current Assets 323 322 329 351 369
Net Property & Equipment 27 28 28 29 27
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 1 1 1 1 1
Deposits & Other Assets 4 4 4 4 3
Total Assets 374 374 383 405 421
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 15 10 10 14 14
Current Portion Long-Term Debt 2 2 2 2 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 19 15 11 17 13
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 16 14 13 12 13
Total Current Liabilities 54 43 39 46 41
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 51 51 51 51 53
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 1 1 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 133 123 119 124 122
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 768 758 744 735 726
Retained Earnings -527 -506 -481 -455 -427
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 241 252 264 281 299
Total Liabilities & Shareholder's Equity 374 374 383 405 421
Total Common Equity 241 252 264 281 299
Shares Outstanding 52.10 51.90 51.40 50.50 50.50
Book Value Per Share 4.63 4.85 5.14 5.56 5.93